German Pharma Sector Analysis
Single User PDF Format: US$ 600.00
Multi-User License: US$ 1000.00
Hard Copy: US$ 700.00
CD-ROM: US$ 700.00
Germany is one of the largest pharmaceutical markets in the world. Most of the pharma companies in Germany are focused on research, which has led the country to become one of the most advanced pharma markets in the world. The country’s pharmaceutical market is estimated to have generated revenues of more than Euro 23 Billion (US$ 32.2 Billion) in 2009, and a consistent and strong growth is anticipated in the market for the next few years.
Our latest research report “German Pharma Sector Analysis” says that most of the growth in the sector will be driven by new and innovative product launches and increasing exports to the Asian and Eastern European market. At present, exports dominate the overall market and the same trend is expected to continue in future as well.
Moreover, it is anticipated that the market will experience a surge in M&A activities in the R&D segment. Therefore, this particular segment of the industry is anticipated to experience better growth in comparison to the production and manufacturing segment. However, it is expected that most of the major pharma firms will continue to expand their manufacturing capabilities.
The report also covers latest market trends on both company and overall industry level, which give a clear picture about the current industry scenario. Also, it provides a complete overview of the regulatory environment in the country’s pharmaceutical market.
“German Pharma Sector Analysis” provides thoroughly researched information, authentic data and comparable statistics of the German pharmaceutical industry. The report studies industrial developments and competitive landscape to enable clients understand the market structure and its progress in coming years. Overall, the report will prove useful to the clients looking to invest or making joint ventures in Germany’s pharmaceutical market.
Multi-User License: US$ 1000.00
Hard Copy: US$ 700.00
CD-ROM: US$ 700.00
Germany is one of the largest pharmaceutical markets in the world. Most of the pharma companies in Germany are focused on research, which has led the country to become one of the most advanced pharma markets in the world. The country’s pharmaceutical market is estimated to have generated revenues of more than Euro 23 Billion (US$ 32.2 Billion) in 2009, and a consistent and strong growth is anticipated in the market for the next few years.
Our latest research report “German Pharma Sector Analysis” says that most of the growth in the sector will be driven by new and innovative product launches and increasing exports to the Asian and Eastern European market. At present, exports dominate the overall market and the same trend is expected to continue in future as well.
Moreover, it is anticipated that the market will experience a surge in M&A activities in the R&D segment. Therefore, this particular segment of the industry is anticipated to experience better growth in comparison to the production and manufacturing segment. However, it is expected that most of the major pharma firms will continue to expand their manufacturing capabilities.
The report also covers latest market trends on both company and overall industry level, which give a clear picture about the current industry scenario. Also, it provides a complete overview of the regulatory environment in the country’s pharmaceutical market.
“German Pharma Sector Analysis” provides thoroughly researched information, authentic data and comparable statistics of the German pharmaceutical industry. The report studies industrial developments and competitive landscape to enable clients understand the market structure and its progress in coming years. Overall, the report will prove useful to the clients looking to invest or making joint ventures in Germany’s pharmaceutical market.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. MARKET DRIVERS
3.1 Increasing Prevalence of Lifestyle Diseases
3.2 Government Incentives Program
3.3 High Affordability
4. GERMAN PHARMACEUTICAL INDUSTRY PERFORMANCE
4.1 Market Size and Growth
4.2 By Type
4.2.1 Branded Drugs
4.2.2 Generic Drugs
4.3 Domestic Consumption and Export
5. LATEST INDUSTRY TRENDS
6. GOVERNMENT REGULATIONS AND INITIATIVES
7. COMPETITIVE LANDSCAPE
7.1 Industry Structure
7.2 Key M&As
7.3 Key Players
7.3.1 Bayer Schering Pharma
7.3.2 Pfizer Inc.
7.3.3 Boehringer Ingelheim
7.3.4 Abbott Laboratories
7.3.5 Novartis
2. RESEARCH METHODOLOGY
3. MARKET DRIVERS
3.1 Increasing Prevalence of Lifestyle Diseases
3.2 Government Incentives Program
3.3 High Affordability
4. GERMAN PHARMACEUTICAL INDUSTRY PERFORMANCE
4.1 Market Size and Growth
4.2 By Type
4.2.1 Branded Drugs
4.2.2 Generic Drugs
4.3 Domestic Consumption and Export
5. LATEST INDUSTRY TRENDS
6. GOVERNMENT REGULATIONS AND INITIATIVES
7. COMPETITIVE LANDSCAPE
7.1 Industry Structure
7.2 Key M&As
7.3 Key Players
7.3.1 Bayer Schering Pharma
7.3.2 Pfizer Inc.
7.3.3 Boehringer Ingelheim
7.3.4 Abbott Laboratories
7.3.5 Novartis
LIST OF FIGURES:
Figure 3-1: Leading Causes of Death (%), 2009
Figure 4-1: Pharmaceutical Market (Billion Euro), 2008-2012
Figure 4-2: Branded Drugs Market (Billion Euro), 2008-2012
Figure 4-3: Generic Drugs Market (Billion Euro), 2008-2012
Figure 4-4: Share of Branded and Generic Drugs in Pharmaceutical Market (Value Terms), 2009
Figure 4-5: Share of Branded and Generic Drugs in Pharmaceutical Market (Volume Terms), 2009
Figure 4-6: Share of Export in Total Pharmaceutical Market (2009)
Figure 3-1: Leading Causes of Death (%), 2009
Figure 4-1: Pharmaceutical Market (Billion Euro), 2008-2012
Figure 4-2: Branded Drugs Market (Billion Euro), 2008-2012
Figure 4-3: Generic Drugs Market (Billion Euro), 2008-2012
Figure 4-4: Share of Branded and Generic Drugs in Pharmaceutical Market (Value Terms), 2009
Figure 4-5: Share of Branded and Generic Drugs in Pharmaceutical Market (Volume Terms), 2009
Figure 4-6: Share of Export in Total Pharmaceutical Market (2009)
LIST OF TABLES:
Table 7-1: Recent M&As in Pharmaceutical Market
Table 7-2: Bayer Schering Pharma - Strengths & Weaknesses
Table 7-3: Pfizer Inc. - Strengths & Weaknesses
Table 7-4: Boehringer Ingelheim - Strengths & Weaknesses
Table 7-5: Abbott Laboratories - Strengths & Weaknesses
Table 7-6: Novartis - Strengths & Weaknesses
Table 7-1: Recent M&As in Pharmaceutical Market
Table 7-2: Bayer Schering Pharma - Strengths & Weaknesses
Table 7-3: Pfizer Inc. - Strengths & Weaknesses
Table 7-4: Boehringer Ingelheim - Strengths & Weaknesses
Table 7-5: Abbott Laboratories - Strengths & Weaknesses
Table 7-6: Novartis - Strengths & Weaknesses
